Analysts at CIBC initiated coverage on shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) in a note issued to investors on Friday. The brokerage set an “outperform” rating and a $19.00 price target on the biotechnology company’s stock. CIBC’s price target would indicate a potential upside of 74.79% from the stock’s previous close.

MCRB has been the subject of several other research reports. Seaport Global Securities restated a “buy” rating and set a $20.00 price target on shares of Seres Therapeutics in a research note on Friday, October 6th. Cantor Fitzgerald restated a “buy” rating on shares of Seres Therapeutics in a research note on Wednesday, August 30th. ValuEngine lowered shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, September 21st. BidaskClub upgraded shares of Seres Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, July 25th. Finally, Zacks Investment Research upgraded shares of Seres Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a research note on Friday, July 14th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company. Seres Therapeutics currently has an average rating of “Buy” and a consensus price target of $18.00.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.59) by ($0.10). Seres Therapeutics had a negative return on equity of 80.21% and a negative net margin of 441.38%. The company had revenue of $3.00 million for the quarter, compared to analysts’ expectations of $3.00 million. During the same quarter in the previous year, the business earned ($0.70) EPS. The company’s revenue for the quarter was up .0% on a year-over-year basis.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/cibc-initiates-coverage-on-seres-therapeutics-inc-mcrb/1627778.html.

A number of institutional investors have recently added to or reduced their stakes in the stock. Parametric Portfolio Associates LLC grew its stake in Seres Therapeutics by 1.3% in the 1st quarter. Parametric Portfolio Associates LLC now owns 21,335 shares of the biotechnology company’s stock valued at $240,000 after buying an additional 279 shares in the last quarter. California State Teachers Retirement System grew its stake in Seres Therapeutics by 1.1% in the 2nd quarter. California State Teachers Retirement System now owns 36,280 shares of the biotechnology company’s stock valued at $410,000 after buying an additional 400 shares in the last quarter. Teachers Advisors LLC grew its stake in Seres Therapeutics by 1.2% in the 2nd quarter. Teachers Advisors LLC now owns 38,758 shares of the biotechnology company’s stock valued at $438,000 after buying an additional 450 shares in the last quarter. Schwab Charles Investment Management Inc. grew its stake in Seres Therapeutics by 0.5% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 91,543 shares of the biotechnology company’s stock valued at $1,035,000 after buying an additional 494 shares in the last quarter. Finally, American International Group Inc. grew its stake in Seres Therapeutics by 7.1% in the 1st quarter. American International Group Inc. now owns 10,977 shares of the biotechnology company’s stock valued at $124,000 after buying an additional 727 shares in the last quarter. Institutional investors and hedge funds own 74.76% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.